Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. briscrew

BriScrew

BioResorbable Ostheosynthesis Implant

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BriScrew project word cloud

Explore the words cloud of the BriScrew project. It provides you a very rough idea of what is the project "BriScrew" about.

fractures    remove    extremely    too    treatment    surgery    bioresorbable    merely    alloy    payback    silver    stress    operation    off    temperature    investment    risk    aluminium    biodegradable    medicine    prevent    pain    hospital    commercializing    employees    conventional    revolutionary    magnesium    secondary    global    performed    individuals    2m    earth    feeling    profit    7m    81    purified    implant    hire    sell    mg    healing    q3    13    stimulates    2020    natural    5    removal    screw    osteosynthesis    roi    foresee    shielding    zirconium    assurance    95    disease    engineering    almost    rare    injuries    orthopaedic    900    reduces    composition    total    implants    team    patient    earn    standard    zn    time    market    sales    infections    pay    titanium    stiff    materials    steel    launch    quality    commercialization    metal    bri    introduce    surgical    ca    bone    generate    unpredictable    qualified    healthcare    frequently    organism    adverse    minimize    risks    alloyed    gold    screws    consists   

Project "BriScrew" data sheet

The following table provides information about the project.

Coordinator		 BRI.TECH GMBH 

Organization address
address: ROSSMANNGASSE 21/4
city: GRAZ
postcode: 8010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Austria [AT]
 Project website http://britech.eu/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRI.TECH GMBH AT (GRAZ) coordinator 50˙000.00

Map

 Project objective

In the EU, 20 % of all hospital treated injuries are bone fractures. If surgical treatment of bone fractures is necessary, it is currently performed with standard metal implants. Conventional gold-standard titanium or steel implants are too stiff, have adverse effects on the patient (feeling of pain during temperature changes) and lead to stress-shielding. Their usage is associated to the risk of infections and bone loss. Often a secondary surgery for removal is needed which is associated with almost 50 % higher healthcare costs. When Mg-based implants are used they are frequently alloyed with rare earth elements, aluminium, silver or zirconium. However, zirconium reduces the healing properties, aluminium and rare earth elements may remain in the organism and can lead to unpredictable effects, while the application of silver might result in a silver-disease.

Within the BRI.SCREW project we will introduce to the market revolutionary osteosynthesis implants that do not need surgical removal. We will use our own bioresorbable magnesium alloy which consists merely out of extremely high purified natural materials including Mg, Ca and Zn. BRI.SCREW is 100 % biodegradable, stimulates the healing process of the bone and has no side effects due to the implant's composition. Our orthopaedic implants will prevent the need of a second operation to remove the implant and will therefore minimize patient costs and surgical risks.

Our team consists of highly qualified individuals with experience in medicine, engineering and quality assurance. The investment in BRI.SCREW will pay off. We have estimated that after 5 years from launch, we will sell in total 81.900 BRI.SCREWs (sales €13.2M), hire 10 technical employees, and manage 5% of the global market. We will earn €8.7M profit and generate a ROI of 3.95 by commercializing this technology. We foresee the payback time in 2 years after commercialization (in Q3 of 2020).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRISCREW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRISCREW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More